Literature DB >> 30789057

Magnetic resonance texture analysis utility in differentiating intraparenchymal neurosarcoidosis from primary central nervous system lymphoma: a preliminary analysis.

Girish Bathla1, Neetu Soni2, Raymondo Endozo3, Balaji Ganeshan4.   

Abstract

PURPOSE: Neurosarcoidosis and primary central nervous system lymphomas, although distinct disease entities, can both have overlapping neuroimaging findings. The purpose of our preliminary study was to assess if magnetic resonance texture analysis can differentiate parenchymal mass-like neurosarcoidosis granulomas from primary central nervous system lymphomas.
METHODS: A total of nine patients was evaluated, four with parenchymal neurosarcoidosis granulomas and five with primary central nervous system lymphomas. Magnetic resonance texture analysis was performed with commercial software using a filtration histogram technique. Texture features of different sizes and variations in signal intensity were extracted at six different spatial scale filters, followed by feature quantification using statistical and histogram parameters and 36 features were analysed for each sequence (T1-weighted, T2-weighted, fluid-attenuated inversion recovery, diffusion-weighted, apparent diffusion coefficient, T1-post contrast). The non-parametric Mann-Whitney test was used to evaluate the differences between different texture parameters.
RESULTS: The differences in distribution of entropy on T2-weighted imaging, apparent diffusion coefficient and T1-weighted post-contrast images were statistically significant on all spatial scale filters. Magnetic resonance texture analysis using medium and coarse spatial scale filters was especially useful in discriminating neurosarcoidosis from primary central nervous system lymphomas for mean, mean positive pixels, kurtosis, and skewness on diffusion-weighted imaging ( P < 0.004-0.030). At spatial scale filter 5, entropy on T2-weighted imaging ( P = 0.001) was the most useful discriminator with a cut-off value of 6.12 ( P = 0.001, area under the curve (AUC)-1, sensitivity (Sn)-100%, specificity (Sp)-100%), followed by kurtosis and skewness on diffusion-weighted imaging with a cut-off value of -0.565 ( P = 0.011, AUC-0.97, Sn-100%, Sp-83%) and-0.365 ( P = 0.008, AUC-0.98, Sn-100%, Sp-100%) respectively.
CONCLUSION: Filtration histogram-based magnetic resonance texture analysis appears to be a promising modality to distinguish parenchymal neurosarcoidosis granulomas from primary central nervous system lymphomas.

Entities:  

Keywords:  MRI; Texture analysis; histogram; neurosarcoidosis; primary central nervous system lymphoma

Mesh:

Substances:

Year:  2019        PMID: 30789057      PMCID: PMC6512209          DOI: 10.1177/1971400919830173

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  20 in total

Review 1.  Texture analysis: a review of neurologic MR imaging applications.

Authors:  A Kassner; R E Thornhill
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-15       Impact factor: 3.825

Review 2.  Texture analysis of medical images.

Authors:  G Castellano; L Bonilha; L M Li; F Cendes
Journal:  Clin Radiol       Date:  2004-12       Impact factor: 2.350

3.  Computer-aided diagnosis of hepatic fibrosis: preliminary evaluation of MRI texture analysis using the finite difference method and an artificial neural network.

Authors:  Hiroki Kato; Masayuki Kanematsu; Xuejun Zhang; Masanao Saio; Hiroshi Kondo; Satoshi Goshima; Hiroshi Fujita
Journal:  AJR Am J Roentgenol       Date:  2007-07       Impact factor: 3.959

4.  Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis?

Authors:  Francesca Ng; Robert Kozarski; Balaji Ganeshan; Vicky Goh
Journal:  Eur J Radiol       Date:  2012-11-26       Impact factor: 3.528

5.  Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.

Authors:  Zhaohai Yang; Laura H Tang; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

6.  MRI texture analysis in multiple sclerosis.

Authors:  Yunyan Zhang
Journal:  Int J Biomed Imaging       Date:  2011-11-16

Review 7.  Overview of neurosarcoidosis: recent advances.

Authors:  Renata Hebel; Mirosława Dubaniewicz-Wybieralska; Anna Dubaniewicz
Journal:  J Neurol       Date:  2014-09-07       Impact factor: 4.849

8.  Classification of cerebral lymphomas and glioblastomas featuring luminance distribution analysis.

Authors:  Toshihiko Yamasaki; Tsuhan Chen; Toshinori Hirai; Ryuji Murakami
Journal:  Comput Math Methods Med       Date:  2013-06-06       Impact factor: 2.238

9.  Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?

Authors:  Fergus Davnall; Connie S P Yip; Gunnar Ljungqvist; Mariyah Selmi; Francesca Ng; Bal Sanghera; Balaji Ganeshan; Kenneth A Miles; Gary J Cook; Vicky Goh
Journal:  Insights Imaging       Date:  2012-10-24

Review 10.  CT texture analysis using the filtration-histogram method: what do the measurements mean?

Authors:  Kenneth A Miles; Balaji Ganeshan; Michael P Hayball
Journal:  Cancer Imaging       Date:  2013-09-23       Impact factor: 3.909

View more
  3 in total

1.  Diffuse large B-cell lymphoma relapse presenting as extensive neurolymphomatosis.

Authors:  Pankaj Nepal; Prem P Batchala; Patrice K Rehm; Camilo E Fadul
Journal:  Neuroradiol J       Date:  2020-05-13

Review 2.  Beyond Glioma: The Utility of Radiomic Analysis for Non-Glial Intracranial Tumors.

Authors:  Darius Kalasauskas; Michael Kosterhon; Naureen Keric; Oliver Korczynski; Andrea Kronfeld; Florian Ringel; Ahmed Othman; Marc A Brockmann
Journal:  Cancers (Basel)       Date:  2022-02-07       Impact factor: 6.639

3.  Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis.

Authors:  Carolin Otto; Oliver Wengert; Nadine Unterwalder; Christian Meisel; Klemens Ruprecht
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.